ELTP (Elite Pharmaceuticals) Total Assets: $126.4 Mil (As of Dec. 2025)


ELTP Elite Pharmaceuticals Inc ELTP
42 GF Score
Price $0.40
GF Value $0.57
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Elite Pharmaceuticals Total Assets?

Elite Pharmaceuticals ELTP +2.62% 42 Total Assets is $126.4 Mil as of Dec. 2025. GuruFocus rates ELTP with a GF Score™ of 42/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 1 warning sign investors should review.

Elite Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 was $126.4 Mil.

During the past 12 months, Elite Pharmaceuticals's average Total Assets Growth Rate was 27.70% per year. During the past 3 years, the average Total Assets Growth Rate was 47.30% per year. During the past 5 years, the average Total Assets Growth Rate was 33.80% per year. During the past 10 years, the average Total Assets Growth Rate was 13.80% per year.

During the past 13 years, Elite Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 53.40%. The lowest was -5.00%. And the median was 8.20%.

Total Assets is connected with ROA %. Elite Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 was 61.05%. Total Assets is also linked to Revenue through Asset Turnover. Elite Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 was 0.26.

Elite Pharmaceuticals  (OTCPK:ELTP) Total Assets Explanation

Total Assets is connected with ROA %.

Elite Pharmaceuticals's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=74.376/( (117.248+126.413)/ 2 )
=74.376/121.8305
=61.05 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Elite Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=31.589/( (117.248+126.413)/ 2 )
=31.589/121.8305
=0.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Elite Pharmaceuticals Total Assets Related Terms

Elite Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Elite Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elite Pharmaceuticals Total Assets Chart

Elite Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.19 35.15 40.90 83.65 96.39

Elite Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 90.76 96.39 111.34 117.25 126.41
ELTP
42GF Score
Elite Pharmaceuticals Inc ELTP
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elite Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Elite Pharmaceuticals's Total Assets for the fiscal year that ended in Mar. 2025 is calculated as

Total Assets=Total Equity (A: Mar. 2025 )+Total Liabilities (A: Mar. 2025 )
=53.515+42.872
=96.4

Elite Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=80.314+46.099
=126.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $126.4 Mil mean?
Elite Pharmaceuticals (ELTP) has a Total Assets of $126.4 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Elite Pharmaceuticals and its competitors.
Is Elite Pharmaceuticals' Total Assets too high?
Elite Pharmaceuticals' current Total Assets is $126.4 Mil. Overall, Elite Pharmaceuticals has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Total Assets compare to SIGA and ORGO?
Elite Pharmaceuticals' Total Assets of $126.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Elite Pharmaceuticals and its competitors. Elite Pharmaceuticals's current Total Assets is $126.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.40 — trading 30.7% below its estimated fair value. The current Total Assets is $126.4 Mil. Elite Pharmaceuticals' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Total Assets is $126.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?

Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued. The current stock price of $0.40 is trading 30.7% below its estimated GF Value™ of $0.57. GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.

Key valuation signals for ELTP:

  • Total Assets: $126.4 Mil
  • GF Value™: $0.57 vs. price of $0.40 (30.7% below fair value)
  • GF Score™: 42/100 with 1 warning sign

No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elite Pharmaceuticals Business Description

Address 165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
42GF Score

Get the complete analysis for ELTP

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.40
Price
$0.57
GF Value